Considering that abnormalities in the p53/MDM2/ARF pathway are identified in half of neuroblastoma cases, RUNX1-mediated ARF upregulation resulting in p53 stabilization may function in at least some of the remaining neuroblastoma cases (Figure 3A). This evidence concerns the gene CDKN2A and neuroblastoma.